Hosted by BZ Group · 🇺🇸 US · EN · 66 episodes
Established thought leaders with verified media credentials.
Your daily pharmaceutical news briefing — FDA decisions, clinical trial results, biotech M&A, and drug pipeline updates in under 15 minutes, every weekday. Hosted by Alex Mercer and Maya Patel. Plus a Weekend Edition every Sunday synthesizing the week's biggest moves in pharma and biotech. Covering drug approvals, pharma industry deals, biopharma investing, and healthcare market intelligence. Smart, fast, and built for professionals who need to stay ahead.Hosts voices are AI created
BZ Group hosts The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus, a science show with 66 episodes published.
SCOTUS unanimously backs Hikma's skinny-label Vascepa generic, reshaping patent defense for branded pharma. ADC Therapeutics drops 50%+ on LOTIS-5 death rate (13.2% vs 4.6%), biotech M&A crosses $106B in 2026, and Legend
Show notesPart 2 of The Pharma Closeout's ASCO 2026 special covers the closing days, Monday June 1 and Tuesday June 2 — net-new readouts plus resolution of Part 1's June 1-2 watch-list. HEADLINE: izalontamab brengitecan (iza-bren)
Show notesASCO 2026 comprehensive opening-weekend recap (28 readouts through Sunday, May 31). Headline: Revolution Medicines' RASolute 302 doubles overall survival in second-line pancreatic cancer (daraxonrasib, 13.2 vs 6.7months,
Show notesRevMed's ASCO pancreatic cancer data earn 'unprecedented' from three major outlets — potential paradigm shift in a historically intractable tumor. Plus ivonescimab's 34% OS improvement with caveats,Pfizer-Innovent's $10.
Show notesPfizer and Innovent strike a deal worth up to $10.5B for 12 cancer programs — the sixth mega-licensing deal out of China since last July. BMS wins Phase 3 for Pomalyst successor mezigdomide at ASCO 2026. Merck, Agios, Ma
Show notesBepirovirsen hits 19% functional cure rate in Phase 3 chronic HBV trials — a first for a disease affecting 300 million. Plus Spero's 245% surge on tebipenem, AstraZeneca's Imfinzi NMIBC approval, CVS restoring Lilly obes
Show notesPfizer's 25-valent pneumococcal shot shows 8.8x–15x higher antibody levels vs. Prevnar 20 in Phase 2, advancing to Phase 3. BMS deploys Claude across 30,000+ employees in landmark pharma-AI deal. Lilly acquires Engage Bi
Show notesTakeda hit with $885M pay-for-delay verdict over generic Amitiza delay. UCB's Bimzelx beats AbbVie's Skyrizi 49% vs 38% on ACR50 in PsA head-to-head. Trump bought up to $680K in Eli Lilly stock while admin promoted obesi
Show notesRegeneron's fianlimab misses PFS endpoint in melanoma, erasing ~$8B in market cap. Supreme Court rejects IRA pricing challenges from six pharma companies. FDA approves AstraZeneca's first-in-class Baxfendy for hypertensi
Show notesThree top FDA positions now in temporary hands as CDER's Høeg follows Makary out the door. Roche's Tecentriq wins ctDNA-guided bladder cancer approval with 36% DFS and 41% OS risk reductions paired with Natera's Signater
Show notesAstraZeneca's VOLGA trial hits EFS and OS incisplatin-ineligible bladder cancer, putting Imfinzi squarely in Keytruda's lane. Plus: Regenxbio's Duchenne gene therapy heads for FDA filing amid safetysignals, a brain tumor
Show notesFDA approves Beqalzi (sonrotoclax) for mantle cell lymphoma — the first new BCL-2 inhibitor in a decade, directly challenging AbbVie's Venclexta franchise. Takeda slashes 4,500 jobs in a $1.26B restructuring; Lilly and N
Show notesFDA Commissioner Makary resigns; Kyle Diamantas steps in as acting chief amid regulatory upheaval. BMS and Hengrui ink $15.2B alliance across 13 programs in oncology, hematology, and immunology. Lilly's Foundayo maintain
Show notesCSL's $5B write-down from the Vifor Pharma acquisition sends shares to a nine-year low — the largest single-day drop on record. Inhibrx's INBRX-106 posts 44% ORR vs Keytruda's 21% in head and neck cancer. PlusRezdiffra c
Show notesFDA approves Vyvgart for all adult gMG serotypes two daysbefore PDUFA — argenx locks in broadest MG label with no FcRn rival in seronegative disease. Plus Merck's $6.7B Terns completion, Avalo's Phase 2 HS win, and Gilea
Show notesFDA leadership in crisis — multiple outlets report Trump will fire Commissioner Makary after 14 turbulent months. Leqembi SC review extended three months to August 24. Bayer acquires Perfuse for $2.45B; Daiichi Sankyo ta
Show notesAngelini Pharma pays $4.1B cash for Catalyst Pharmaceuticals — the fourth biotech buyout this month. Atara surges 40%+ on FDA path to resubmit tab-cel BLA. Roche acquires PathAI in $1B+ AI diagnostics deal. Duchenne take
Show notesBayer bets up to $2.45B on glaucoma drug maker PerfuseTherapeutics — its biggest pharma deal in years. Novo's oral Wegovy hits $355M in Q1, the strongest GLP-1 launch by volume in the US. Plus UCB's $2.2B Candid deal, GS
Show notesMyqorzo hits both endpoints in ACACIA-HCM, opening amultibillion-dollar HCM market Camzyos can't reach. Plus: Pfizer scraps its last CD47 program from the $2.3B Trillium acquisition, Madrigal licenses Arrowhead's PNPLA3
Show notesSupreme Court grants emergency stay restoring mifepristone access — and the ruling's implications hit every drugmaker's risk model. Plus: Arvinas/Pfizer's vepdegestrant becomes the first PROTAC approved by the FDA, UCB a
Show notesSponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
To pitch The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus, visit https://podcasters.spotify.com/pod/show/bin-zhu for contact information, then craft a tight one-paragraph hook that ties your expertise to a gap in their recent science coverage.
The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus is hosted by BZ Group. The show is categorised under science (life) and has published 66 episodes.
The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus has published 66 episodes.
The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus regularly covers science, life. It sits in the science category, with a life focus.
The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus is accessible for guests with genuine science expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus average 12 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 10 days ago.
